127 related articles for article (PubMed ID: 9533060)
1. Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers.
Tenero DM; Martin DE; Ilson BE; Boyle DA; Boike SC; Carr AM; Lundberg DE; Jorkasky DK
Ann Pharmacother; 1998 Mar; 32(3):304-8. PubMed ID: 9533060
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and urinary excretion of eprosartan in Chinese healthy volunteers of different gender.
Xu HR; Chen WL; Li XN; Liu GY; Chu NN; Yu C
Pharmazie; 2007 Oct; 62(10):782-4. PubMed ID: 18236785
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.
Martin DE; Chapelsky MC; Ilson B; Tenero D; Boike SC; Zariffa N; Jorkasky DK
J Clin Pharmacol; 1998 Feb; 38(2):129-37. PubMed ID: 9549643
[TBL] [Abstract][Full Text] [Related]
4. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers.
Martin DE; Tompson D; Boike SC; Tenero D; Ilson B; Citerone D; Jorkasky DK
Br J Clin Pharmacol; 1997 Jun; 43(6):661-4. PubMed ID: 9205830
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease.
Kovacs SJ; Tenero DM; Martin DE; Ilson BE; Jorkasky DK
Pharmacotherapy; 1999 May; 19(5):612-9. PubMed ID: 10331824
[TBL] [Abstract][Full Text] [Related]
6. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers.
Kazierad DJ; Martin DE; Blum RA; Tenero DM; Ilson B; Boike SC; Etheredge R; Jorkasky DK
Clin Pharmacol Ther; 1997 Oct; 62(4):417-25. PubMed ID: 9357393
[TBL] [Abstract][Full Text] [Related]
7. A dose proportionality study of eprosartan in healthy male volunteers.
Chapelsky MC; Martin DE; Tenero DM; Ilson BE; Boike SC; Etheredge R; Jorkasky DK
J Clin Pharmacol; 1998 Jan; 38(1):34-9. PubMed ID: 9597557
[TBL] [Abstract][Full Text] [Related]
8. The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.
Miller AK; DiCicco RA; Freed MI
Clin Ther; 2002 Jul; 24(7):1062-71. PubMed ID: 12182252
[TBL] [Abstract][Full Text] [Related]
9. A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies.
Blum RA; Kazierad DJ; Tenero DM
Pharmacotherapy; 1999 Apr; 19(4 Pt 2):79S-85S. PubMed ID: 10213526
[TBL] [Abstract][Full Text] [Related]
10. Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan.
Tenero D; Martin D; Chapelsky M; Ilson B; Boike S; Patterson S; Keogh J; Rodriguez S; Jorkasky D
Pharmacotherapy; 1998; 18(1):42-50. PubMed ID: 9469680
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food.
Tenero D; Martin D; Ilson B; Jushchyshyn J; Boike S; Lundberg D; Zariffa N; Boyle D; Jorkasky D
Biopharm Drug Dispos; 1998 Sep; 19(6):351-6. PubMed ID: 9737815
[TBL] [Abstract][Full Text] [Related]
12. Effect of age and gender on the pharmacokinetics of eprosartan.
Tenero DM; Martin DE; Miller AK; Ilson B; Boike SC; Zariffa N; Jorkasky DK
Br J Clin Pharmacol; 1998 Sep; 46(3):267-70. PubMed ID: 9764969
[TBL] [Abstract][Full Text] [Related]
13. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
Kakuda TN; Falcon RW
Pharmacotherapy; 2006 Aug; 26(8):1060-8. PubMed ID: 16863482
[TBL] [Abstract][Full Text] [Related]
14. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
[TBL] [Abstract][Full Text] [Related]
15. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men.
Ilson BE; Boike SC; Martin DE; Freed MI; Zariffa N; Jorkasky DK
Clin Pharmacol Ther; 1998 Apr; 63(4):471-81. PubMed ID: 9585802
[TBL] [Abstract][Full Text] [Related]
16. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Small DS; Farid NA; Li YG; Ernest CS; Payne CD; Salazar DE; Winters KJ
Curr Med Res Opin; 2008 Aug; 24(8):2251-7. PubMed ID: 18786302
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
[TBL] [Abstract][Full Text] [Related]
18. Eprosartan.
McClellan KJ; Balfour JA
Drugs; 1998 May; 55(5):713-8; discussion 719-20. PubMed ID: 9585867
[TBL] [Abstract][Full Text] [Related]
19. Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus.
Martin DE; DeCherney GS; Ilson BE; Jones BA; Boike SC; Freed MI; Jorkasky DK
J Clin Pharmacol; 1997 Feb; 37(2):155-9. PubMed ID: 9055142
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.
Sekar VJ; Lefebvre E; De Paepe E; De Marez T; De Pauw M; Parys W; Hoetelmans RM
Antimicrob Agents Chemother; 2007 Mar; 51(3):958-61. PubMed ID: 17210768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
